Journal article

Effect of the Glutamate NMDA Receptor Antagonist Memantine as Adjunctive Treatment in Borderline Personality Disorder: An Exploratory, Randomised, Double-Blind, Placebo-Controlled Trial

Jayashri Kulkarni, Natalie Thomas, Abdul-Rahman Hudaib, Emorfia Gavrilidis, Jasmin Grigg, Raelene Tan, Jacinta Cheng, Amelia Arnold, Caroline Gurvich

CNS DRUGS | ADIS INT LTD | Published : 2018


BACKGROUND: Borderline personality disorder (BPD) is a complex, severe and highly stigmatised psychiatric illness. Several lines of evidence highlight the causal link between chronic stress, glucocorticoid response to stress and glutamatergic overactivity as a key event in the pathophysiology of BPD. Therefore, molecular mechanisms capable of regulating glutamate excitotoxicity represent novel and potentially promising treatment targets. Memantine-HCl is a voltage-dependent N-methyl-D-aspartate (NMDA) receptor 'channel blocker' that selectively blocks pathological glutamate overactivity. OBJECTIVE: The aim of the current study was to determine if memantine can improve BPD symptoms. METHOD: A..

View full abstract


Awarded by National Health and Medical and Research Council (NHMRC)

Funding Acknowledgements

National Health and Medical and Research Council (NHMRC) Project Grant: 1129815 and Private Philanthropic Grant provided by Dr. Jeff Wolinski, C/o Monash University Fundraising Department, Faculty of Medicine, Nursing and Health Sciences.